Differentiation therapy: Targeting human renal cancer stem cells with interleukin 15

Sandy Azzi, Stefania Bruno, Julien Giron-Michel, Denis Clay, Aurore Devocelle, Michela Croce, Silvano Ferrini, Salem Chouaib, Aimé Vazquez, Bernard Charpentier, Giovanni Camussi, Bruno Azzarone, Pierre Eid

Research output: Contribution to journalArticle

Abstract

Background Many renal cancer patients experience disease recurrence after immunotherapy or combined treatments due to persistence of cancer stem cells (CSCs). The identification of reliable inducers of CSC differentiation may facilitate the development of efficient strategies for eliminating CSCs. We investigated whether interleukin 15 (IL-15), a regulator of kidney homeostasis, induces the differentiation of CD105-positive (CD1051) CSCs from human renal cancers. Methods CD1051 CSCs were cultured to preserve their stem cell properties and treated with recombinant human IL-15 (rhIL-15) to evaluate their ability to differentiate, to acquire sensitivity to chemotherapeutic drugs, and to form spheroids in vitro and tumors in vivo. Expression of stem cell and epithelial markers were studied by flow cytometry, immunocytochemistry, and immunoblotting. Identification of a CSC side population fraction and its sensitivity to chemotherapy drugs and expression of ATP-binding cassette (ABC) transporters and aldehyde dehydrogenase (ALDH) activities were determined by flow cytometry. Spheroid formation was determined in limiting dilution assay. Xenograft tumors were generated in severe combined immunodeficient mice (n = 12-18 mice per group). All statistical tests were two-sided. Results CD1051 CSCs treated with rhIL-15 at 10 pg/mL differentiated into cells expressing epithelial markers. rhIL-15 induced epithelial differentiation of all CD1051 CSCs subsets and blocked CSC self-renewal (sphere-forming ability) and their tumorigenic properties in severe combined immunodeficient mice. Vinblastine and paclitaxel induced statistically significant higher levels of apoptosis in rhIL-15-differentiated epithelial cells compared with CD1051 CSCs (mean percentage of apoptotic cells, vinblastine: 33% vs 16.5%, difference = 16.5%, 95% confidence interval = 12.25% to 20.74%, P = .0025; paclitaxel: 35% vs 11.6%, difference = 23.4%, 95% confidence interval = 22.5% to 24.24%, P = .0015). The higher sensitivity of rhIL-15-differentiated epithelial cells to chemotherapeutic drugs was associated with loss of detoxifying mechanisms such as ALDH and ABC transporter activities. Conclusion IL-15 directs the epithelial differentiation of renal CSCs and meets the criteria for a treatment strategy: CSC pool depletion and generation of differentiated nontumorigenic cells that are sensitive to chemotherapeutic agents.

Original languageEnglish
Pages (from-to)1884-1898
Number of pages15
JournalJournal of the National Cancer Institute
Volume103
Issue number24
DOIs
Publication statusPublished - Dec 21 2010

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Azzi, S., Bruno, S., Giron-Michel, J., Clay, D., Devocelle, A., Croce, M., Ferrini, S., Chouaib, S., Vazquez, A., Charpentier, B., Camussi, G., Azzarone, B., & Eid, P. (2010). Differentiation therapy: Targeting human renal cancer stem cells with interleukin 15. Journal of the National Cancer Institute, 103(24), 1884-1898. https://doi.org/10.1093/jnci/djr451